Rx to save patients money: Lift Big Pharma ‘gag orders’ on pharmacists

by Patrick Malone & Associates P.C. | DC Injury Lawyers

Click here for video.

Big Pharma’s notorious middle-men, aka prescription benefit managers or PBMs, are coming under yet more fire — this time over so-called gag orders that they impose on pharmacists they work with, preventing these front-line health care providers from telling patients about cheaper options for drugs.

The New York Times reported that states are leading the push, and soon may be joined by the federal government, to bar companies from preventing this money-saving practice.

Independent pharmacists say that PBMs won’t work with them, if, for example, they tell patients that a brand drug they’ve been prescribed will cost them $125 if they use their health insurance but $100 if they pay cash. Why would the benefit managers do this? Because such a step cuts into their pay, which already may be considerable.

Here’s why: In an unintended consequence of an effort to check soaring drug prices, major employers, insurers, and drug makers helped to launch prescription benefit managers, only to see these middle-men rise in influence and profitability. The benefit managers work with employers, drug makers, insurers, distributors, and pharmacies, dickering over costs and prices, including by establishing lists of products and what should be paid for them (see the Kaiser Health News explanatory video, above). If they wring efficiencies out of the drug supply chain and money gets saved, including with discounts and coupon programs, PBMs take those sums as their share.

But parties they deal with — including drug makers, insurers, and major employers — don’t know details how benefit managers make their money or how much. Their finances can be a “black box” mystery, though it is clear they’re becoming more profitable and powerful than intended, the New York Times says.

The Wall Street Journal reported that financial analysts scrutinized profit margins disclosed by the biggest PBMs. They were low, in the single digits. But outside financial experts noted that benefits managers included in their financial reporting hefty costs for drugs sold — even though they never take delivery of products. That means their actual overhead costs stay low. They don’t have sales, administrative, amortization, or depreciation costs. By taking reality into consideration, PBMs become “exceptionally profitable,” the Journal reported.

The very profitability of these operations, however, may be their own undoing, too. Insurers and pharmacy chains are jumping in to set up PBMs they control. Analysts are watching to see if corporate America — notably the recently announced health care cost-mind alliance of Amazon, Berkshire-Hathaway, and JPMorgan Chase — also find ways around the drug middlemen.

And while it may be briefly satisfying to enjoy the schadenfreude of Big Pharma and insurers finding someone else beating them to their beloved buck, in my practice, I see not only the major harms that patients suffer while seeking medical services but also their struggles to access and afford safe, quality health care. Drug costs keep heading skyward, pushing up patients’ already high anxiety and desperation, driving medical debt, bankruptcies, and the ever-rising cost of U.S. health care.

Individual patients should protect themselves against drug rip-offs by talking with their doctors and pharmacists and doing their own skeptical research, perhaps some online (with lots of caution), and by shopping around. They may want to consider if generics may be a less-expensive option, though Big Pharma’s trying to make these supposedly lower-cost alternatives too pricey to bear, too.

It’s good to see state lawmakers step up to help consumers try to save money by nixing pharmacist gag orders. But federal officials need to do their part — and more — to dig into if and how much PBMs and their practices may be boosting already onerous drug prices, and then to actually do something about it.

In case anyone needs their blood pressure to spike, Martin Shkreli, the smirking hedge-fund brat who became notorious as “Pharma Bro,” resurfaced recently: He’s now calling himself a “fool” and throwing himself on the court’s mercy as a federal judge decides his sentence in his securities fraud case. He’s a smirking twit and deserved the public whipping he got from members of Congress, outraged that he and other hedge-funders were buying up small drug companies with patents or control of niche medications, then hiking the products’ costs to exorbitant levels. Pharma Bro did this with Daraprim, an infection-fighting drug that those with serious conditions like HIV-AIDS consider life-saving.

For all the Washington outcry, and the purported launch of a generic alternative, Daraprim — once $13.50 a pill — hasn’t budged from the nose-bleed Shkreli-set price of $750 per pill.

That’s not just sad, it’s unacceptable. And we Americans, gouged to the nth degree by Big Pharma, need to let our elected officials and taxpayer-supported regulators know that their impotence in oversight can’t continue.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patrick Malone & Associates P.C. | DC Injury Lawyers | Attorney Advertising

Written by:

Patrick Malone & Associates P.C. | DC Injury Lawyers

Patrick Malone & Associates P.C. | DC Injury Lawyers on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.